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METHODOLOGY ARTICLE Open Access
REACTIN: Regulatory activity inference of
transcription factors underlying human diseases
with application to breast cancer
Mingzhu Zhu1, Chun-Chi Liu2,3 and Chao Cheng1,4,5,6*
Abstract
Background: Genetic alterations of transcription factors (TFs) have been implicated in the tumorigenesis of cancers.
In many cancers, alteration of TFs results in aberrant activity of them without changing their gene expression level.
Gene expression data from microarray or RNA-seq experiments can capture the expression change of genes,
however, it is still challenge to reveal the activity change of TFs.
Results: Here we propose a method, called REACTIN (REgulatory ACTivity INference), which integrates TF binding
data with gene expression data to identify TFs with significantly differential activity between disease and normal
samples. REACTIN successfully detect differential activity of estrogen receptor (ER) between ER+ and ER- samples in
10 breast cancer datasets. When applied to compare tumor and normal breast samples, it reveals TFs that are
critical for carcinogenesis of breast cancer. Moreover, Reaction can be utilized to identify transcriptional programs
that are predictive to patient survival time of breast cancer patients.
Conclusions: REACTIN provides a useful tool to investigate regulatory programs underlying a biological process
providing the related case and control gene expression data. Considering the enormous amount of cancer gene
expression data and the increasingly accumulating ChIP-seq data, we expect wide application of REACTIN for
revealing the regulatory mechanisms of various diseases.
Keywords: Transcription factor, ChIP-seq, Gene expression
Background
Transcription factors (TFs) are a family of proteins that
regulate gene expression via binding to specific DNA se-
quences [1], accounting for 10% of genes in human gen-
ome [2,3]. They play instrumental roles in the regulation
of many biological processes, such as development, cell
proliferation, cell cycle progression, and apoptosis [4-8].
Aberrant expression or activation/inactivation of TFs
has been implicated in human diseases [9], particularly,
in a variety of different cancer types [10,11]. As a matter
of fact, a large number of oncogenes and tumor suppres-
sor genes actually encode TFs. For instance, the most
well studied tumor suppressor gene, P53, has been found
to be mutated in over 50% of human cancers [12],
mostly resulting in impaired capability of transcriptional
activation [13].
Microarray experiments have been intensively used to
investigate the mechanism of cancer and have resulted
in the accumulation of enormous amount of data that
are available from the public database such as GEO
(Gene Expression Omnibus) [14]. The microarray data
enable us to identify differentially expressed genes [15],
discover cancer associated gene signatures, and classify
tumors into different subtypes [16,17], which have dra-
matically advanced our understanding about cancer.
However, gene expression profiles of tumor samples can
only capture the down-stream readout of the driving
genetic alterations such as mutations, amplifications and
deletions [18]. The changes of the regulatory program
underlying a cancer type may not be directly detected
from the microarray data. For example, although muta-
tion of P53 gene is known to be a driving event for
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carcinogenesis in many cancer types [19,20], in most
cases there is no significant P53 expression difference
between tumor and normal samples: mutation abolishes
its transcriptional activity by impacting its DNA binding
capacity or protein stability without changing its mRNA
expression level [21-23].
Although the alteration of a TF cannot be detected dir-
ectly from the expression changes of its corresponding
mRNA, we expect that alteration of the TF can be re-
vealed by using the expression changes of its target
genes. Based on this idea, Rhodes et al. [18] proposed
to identify conditional regulatory programs by defining
gene expression signatures (differentially expressed ge-
nes between cancer and normal samples) and putative
TF regulatory signatures (a set of genes containing bin-
ding sites of a TF) and examining their overlap. The TFs
with enriched regulatory signatures in gene expression
signature of cancer were reported to be cancer associa-
ted [18]. Previously, we also proposed a Kolmogorov–
Smirnov test like method to infer activity changes of TFs
based on their binding association with sorted expres-
sion profiles [24,25]. All these methods defined TF-gene
regulatory relationships by searching putative TF binding
sites in promoters of genes, in which the accuracy was
affected by both high false positive rate and high false
negative rate.
The recent advancement of experimental technologies
such as chromatin immunoprecipitation followed by
massively parallel DNA sequencing (ChIP-seq) [26] or
microarray hybridization (ChIP-chip) [27] enables us to
more accurately determine genome wide occupation of
TFs. Given the ChIP-seq or ChIP-chip data, we can de-
fine a list of target genes for a TF based on the presence
of binding peaks in their regulatory DNA regions
[28-30]. Alternatively, we can also quantify the binding
potential of a TF to all genes, resulting in a continu-
ous representation of TF-gene regulatory relationships
[31-33]. In the past few years, a large amount of ChIP-
seq and ChIP-chip data for various TFs have been gen-
erated by several research consortiums, e.g. ENCODE
(The Encyclopedia of DNA Elements) [34,35], and by
individual laboratories [36,37].
In this study, we developed a novel method called
REACTIN (REgulatory ACTivity INference) to infer TFs
that exhibit significantly differential activity in the dis-
ease samples versus the normal controls. The REACTIN
algorithm integrates case–control gene expression data
with TF binding profiles from ChIP-seq or ChIP-chip ex-
periments. To compare the REACTIN algorithm with
the other method, we examined the performance of the
GSEA method to infer TF activity using the same da-
tasets [38]. We found that GSEA does not always give
rise to biological sensible results and the results were
often sensitive to the definition of target gene sets of
TFs. Further investigation indicated that poor perform-
ance of GSEA was mainly caused by the target gene sets
of TFs, which were often difficult to be determined
based on ChIP-seq or ChIP-chip data. This motivated us
to propose the REACTIN algorithm, which applied a
similar rank based framework as GSEA but improved it
by defining TF-gene regulatory relationship in a quanti-
tative manner.
We evaluated the performance of REACTIN in 10
breast cancer gene expression datasets, all of them
containing both ER+ and ER- samples. The method suc-
cessfully identified ER alpha as the TF that showed sig-
nificantly higher regulatory activities in ER+ than in ER-
breast cancer samples. In addition, it also detected the
activity difference of two other breast cancer associated
TFs, FOXA1 and GATA3, in ER+ versus ER- samples.
Using breast cancer as an example, we also demon-
strated that the REACTIN algorithm can be used to
investigate regulatory mechanisms governing different
breast cancer subtypes by comparison with normal tis-
sues, in addition to identifying TF activity associated
with patient survival in their activities. Considering the
huge accumulation of microarray data that have been
accumulated and the increasingly availability of TF bin-
ding data, we expect that REACTIN can be widely used
to study the regulatory mechanisms of many human
diseases.
Results
Overview of REACTIN algorithm for TF activity inference
To investigate the regulatory mechanism underlying
a specific cancer type, we developed a method called
REACTIN (REgulatory ACTivity INference) to infer TFs
that show significantly differential activity in the tumor
samples versus the normal controls. Given the case–
control gene expression data (cancer versus normal sam-
ples), we would expect to see the differential expression
of target genes of a TF with altered activity in tumor
samples. Similar to the GSEA (Gene Set Enrichment
Analysis) method [38], REACTIN ranks all genes based
on the expression changes in case versus control sam-
ples, and then examines their potential being bound by a
TF by referring to its ChIP-seq data. Here the rationale
is that it is often difficult and less effective to define a
target gene set for a TF due to the quantitative nature of
TF-gene interactions [33]. Thus, we used a probabilistic
model to predict the target genes of a TF: for each gene
we assign a score to measure its probability of being reg-
ulated by the TF. Briefly, REACTIN takes a three-step
procedure to identify significant genes (Figure 1).
Step 1 The probabilistic measure of TF-gene
interactions based on ChIP-seq data. Based on
ChIP-seq data, we calculated the binding affinity
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of a TF with all human genes using a
probabilistic model called TIP (Target
Identification from Profile) [31]. For a TF, TIP
builds a characteristic, average profile of binding
around the TSS (Transcription Start Site) of all
genes and then uses this profile to weight the
sites associated with a given gene, providing a
continuous-valued score of this TF for each
gene. The score provides a metric that
quantifies the binding affinity of a TF with a
gene. We have collected 424 human ChIP-seq
samples from the ENCODE project [39], based
on which we constructed a TF target database
that probabilistically measures TF-gene
interactions.
Step 2 Calculation of regulatory activity scores (RAS)
for all TFs (See Methods). We calculate the
t-scores for all genes by comparing their
expression levels in case samples and control
samples, and sort them to obtain a ranked list.
The RAS is calculated by walking down the list
and a running-sum statistic is used to capture
the correlation between gene expression change
(the t-score) and TF binding potential (from
ChIP-seq). If genes with higher ranks in the list
tend to have higher binding probabilities by a
TF, then the TF will achieve a greater RAS
score. As a metric, the RAS can be regarded as
an extended version of the ES in GSEA analysis.
Step 3 Significance estimation and multiple-testing
correction. We estimate the statistical
significance of the RAS by using an empirical
phenotype-based permutation test procedure
that preserves the complex correlation structure
of the gene expression data. Specifically, we
permute the case/control class labels and
recompute the RAS of the gene set in the
permuted data, which generates a null
distribution for the RAS. The empirical,
nominal P value of the observed RAS is then
calculated relative to this null distribution. We
calculated the false discovery rate by comparing
the distribution of the RAS with the null
distribution from permutation test.
Evaluation of REACTIN by comparing ER+ with ER- breast
cancer
To test the effectiveness of the REACTIN algorithm, we
applied it to identify TFs with significantly different
regulatory activities between ER+ and ER- breast cancer
samples. Specifically, we collected 10 breast cancer mi-
croarray datasets, each containing both ER+ and ER-
samples (see Table S1 in Additional file 1: Table S1)
[40-49]. ER is a transcription factor that is active in ER+
but not in ER- breast cancer, and its binding profile (ER
alpha) is included in our ChIP-seq data collection. If
REACTIN is effective, we will identify ER as one of the
TFs that shows significantly higher activity in ER+ than
in ER- samples.
Strikingly, REACTIN successfully detected the activity
difference of ER alpha between ER+ and ER- breast
cancer samples in all of the 10 datasets (Figure 2 and
Additional file 2: Table S2). There are 6 ER alpha bind-
ing profiles in our ChIP-seq collection, representing bin-
ding affinities with human genes in two cell lines (T47d
and Ecc1) under three different conditions: two steroid
Figure 1 The workflow of REACTIN algorithm. Step 1: Measure of the binding affinity of a TF with all human genes using TIP. Step 2:
Calculation of regulatory scores (RS) for all TFs. Step 3: Significance estimation and multiple-testing correction.
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hormone treatments (Gen1h and Estrodia1h) and a con-
trol treatment (Dmso2). In all datasets, the ER alpha
binding profiles Haib_T47d_Eralphaa_Gen1h and Haib_
T47d_Eralphaa_Estradia1h were identified to have sig-
nificantly higher activity in ER+ than ER- at the 0.25
false discovery rate (FDR<0.25) (Table S2 in Additional
file 2: Table S2). For example, Table 1 shows the top
10 most differential TFs between ER+ and ER- in Veer
and Wang datasets. As shown, the RAS of Haib_T47d_
Eralphaa_Gen1h is 0.624 in the Veer dataset and
6.538 in the Wang dataset, with a FDR of 0.005 and
0.003, respectively. More importantly, there is a clear
separation between the significant TF binding profiles
and the non-significant ones (Table 1), suggesting a
high specificity of the REACTIN algorithm. As shown
in the Veer dataset, there are 4 significant TF binding pro-
files, all of them with a FDR<0.039; but the fifth most dif-
ferential (based on RAS) profile Haib_T47d_P300_Dmso2
is with a FDR=0.266.
In Figure 3, we use Haib_T47d_Eralphaa_Gen1h in the
Hess dataset as the example to show how the REACTIN
algorithm identifies its activity difference. As shown in
Figure 3a, when genes are sorted in the decreasing order
of their t-scores (ER+ versus ER- samples in Hess data-
set), genes with higher binding possibilities (grey lines
with larger –log10 (P-value)) as calculated by TIP [31]
are more likely to have higher t-scores (i.e. biased to the
left side). This indicates that target genes of ER alpha
are more likely to have higher expression levels in ER+
than in ER- samples, implying the regulatory activity
difference of ER alpha. In fact, the t-score of genes is
significantly correlated with TF binding scores calcula-
ted by TIP with a correlation Rho=0.186 (Figure 3b).
REACTIN captures such a relationship by comparing a
foreground function with a background function as
shown in Figure 3c. The maximum deviation of the two
functions reflects the activity difference of ER alpha bet-
ween ER+ and ER- samples (See “Methods” for details).
Target genes determined by peak-based method (the
green lines in Figure 3a, genes with a ER alpha binding
peaks in [−1000, 500] of their transcriptional start sites)
also tend to have higher t-scores. However, GSEA ana-
lysis failed to identify ER alpha targets (based on Haib_
T47d_Eralphaa_Gen1h binding profile) as a gene set
enriched in differentially expressed genes between ER+





















































































































Figure 2 The activity difference of ER alpha between ER+ and ER- samples in all 10 datasets. Six ER alpha binding profiles are from T47d
or Ecc1 cell lines, and treated with steroid hormone (Gen and Estradia) for 1h or Dmso2 as control. “*” indicates that a ER alpha binding profile
has significantly high activity in ER+ than ER- with P<0.01.
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are two main causes resulting this phenomenon: (1)
many of the target genes identified by peak-based me-
thod may not be ER alpha targets according to TIP
calculated probabilities (Figure 3a); (2) gene set based in-
ference cannot effectively capture the information pro-
vided by TF binding data from ChIP-seq experiments.
It is interesting to observe the influence of ChIP-seq
cell lines and conditions to the results. The REACTIN
algorithm detected more significantly differential activity
of ER alpha between ER+ and ER- for binding profiles in
T47d than in Ecc1 (Figure 2).
Although both T47d and Ecc1 cell lines maintain es-
trogen receptors and are steroid-responsive, T47d is de-
rived from breast epithelial tumor cells and Ecc1 is
derived from endometrial carcinoma cells. As such,
T47d can accurately characterize the ER alpha binding
affinities to genes in breast cancer samples. This explains
why we observed higher regulatory scores for ER alpha
binding profiles from T47d than from Ecc1 in all of the
microarray datasets (Figure 2). Additionally, we observed
an obvious condition effect: ER alpha activity difference
can only be detected when cell lines are treated with
steroid hormones during ChIP-seq experiments, because
target gene binding of ER alpha can be accurately cha-
racterized after treated with hormone than the Dmso2
control (Figure 2).
In addition to ER alpha, we also identified FOXA1 and
GATA3 as the TFs with significantly higher activities in
ER+ than in ER- breast cancer samples (Table 1 and
Additional file 1: Table S1). The association of ER alpha
and FOXA1 with breast cancer have been well defined
[50-53]. Up to now ER alpha is deemed to be one of the
most important molecular factors in the prognosis and
therapy of breast cancer [54]. In ER+ breast cancers ER
alpha inhibits apoptosis of tumor cells [55]. FOXA1 is a
necessary pioneer factor to mediate ER alpha association
with compacted DNA in breast cancer cells [56]. When
FOXA1 is absent, ER alpha cannot interact with DNA
and the expression of ER alpha-mediated genes are
prevented [52]. GATA3, has been shown in a recent stu-
dy to be one of the three genes that are mutated in >10%
of breast cancers [49]. A recent study [57] has shown that
GATA3 associates directly with ER alpha and progeste-
rone receptor. We compared the mRNA expression levels
Table 1 Top 10 TF binding profiles with significantly different activities between ER+ and ER- breast cancer samples in
the Veer and the Wang datasets
The Veer data
Cell line TF Condition Lab RAS Location P-value FDR
T47d Eralphaa Gen1h Haib 6.424 0.174 0 0.005
T47d Eralphaa Estradia1h Haib 6.424 0.174 0 0.011
T47d Foxa1 Dmso2 Haib 5.427 0.174 0 0.036
T47d Gata3 Dmso2 Haib 5.263 0.174 0 0.039
T47d P300 Dmso2 Haib 4.372 0.180 0.002 0.266
Hepg2 Foxa1 Haib 3.905 0.158 0.001 0.413
T47d Eralphaa Dmso2 Haib 3.946 0.247 0.012 0.438
Ecc1 Eralphaa Estradia1h Haib 4.006 0.126 0 0.457
Mcf7 Cmyc Estro Broad 1.710 0.637 0.206 0.695
H1hesc Ctcf Broad 1.710 0.106 0.184 0.701
The Wang data
Cell line TF Condition Lab RAS Location P-value FDR
T47d Eralphaa Gen1h Haib 6.538 0.135 0 0.003
T47d Eralphaa Estradia1h Haib 6.538 0.135 0 0.007
T47d Gata3 Dmso2 Haib 4.874 0.189 0.006 0.142
T47d Foxa1 Dmso2 Haib 5.076 0.189 0.003 0.142
Ecc1 Eralphaa Estradia1h Haib 4.953 0.094 0 0.146
Ecc1 Eralphaa Gen1h Haib 3.929 0.126 0.005 0.872
Hl60 Ctcf Uw -1.042 0.704 0.365 0.901
H1hesc Sin3ak20 Haib 0.735 0.233 0.454 0.921
Gm19239 Ctcf Broad -0.917 0.035 0.417 0.801
A549 Gr Dexd Haib 0.725 0.281 0.444 0.924
The “Location” column shows the percentile of genes at which the maximum deviation is observed. TF binding profiles with a FDR<0.25 are highlighted in bold.
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of ESR1 (ER alpha coding gene), FOXA1 and GATA3 be-
tween ER+ and ER- samples in the microarray data, and
found that all of them are more highly expressed in ER+
samples. For instance, in the Wang dataset, ESR1, FOXA1
and GATA3 showed significantly higher expression le-
vels in ER+ and ER- samples with P=3e-44, P=4e-16 and
P=8e-13, respectively (the Student t-test). These results in-
dicate that the activity difference of these three TFs be-
tween ER+ and ER- samples is at least partially caused by
the their differential expression at the mRNA level. But
we cannot rule out the possibility that in certain samples
regulatory activity is a result of point mutation instead of
expression change.
Transcriptional regulatory programs underlying different
breast cancer subtypes
We next applied the REACTIN algorithm to investigate
the regulatory mechanisms underlying different breast
cancer subtypes. We applied it to the microarray data
published by Ma et al., which contained expression
profiles of 66 samples isolated from ductal carcinoma in
situ (DCIS) or invasive ductal carcinoma (IDC) biopsies.
The samples can be divided into 6 categories: 14 normal
epithelium samples (NE), 9 DCIS-associated malignant
epithelium samples (ISE), 9 IDC-associated invasive epi-
thelium samples (INVE), 14 normal stroma samples away
from the malignant lesion (NS), 11 DCIS-associated ma-
lignant stroma samples (ISS) and 9 IDC-associated inva-
sive stroma samples (INVS).
First, we pooled the samples to obtain 28 normal
breast samples (NE and NS) and 38 tumor samples (ISE,
INVE, ISS and INVS). We identified TF binding profiles
showing significantly differential activities in tumor versus
normal breast samples using the REACTIN algorithm.
Our results indicate that Stat1 and Stat2 are significantly
more active (i.e. their target genes tend to be more highly
expressed) in tumor cells than normal cells (Table 2).
Members of the Stat family play an important role in
regulating breast cancer development [58]. The lack of
Stat1 results in aberrant response to IFN signaling and
Figure 3 REACTIN algorithm identifies significant activity difference of ER alpha (Haib_T47d_Eralphaa_Gen1h) in the Hess dataset.
(a) Genes with higher t-scores (ER+ vs ER-) are more likely to be regulated by ER alpha. Genes are sorted in a decreasing order according to
their t-scores (ER+ vs ER-). The –log10(P-value) is calculated by TIP, indicating the probability of a gene is bound by ER alpha in Haib_T47d_
Eraphaa_Gen1h ChIP-seq data. The green lines indicates ER alpha target genes identified by peak-based method; (b) The correlation between the
t-scores of genes and TF binding scores calculated by TIP; (c) The foreground and background functions for Haib_T47d_Eraphaa_Gen1h binding
profile. The foreground and background functions are defined in Formula (xx) and (xx). Note the maximum deviation is obtained at the 18.9%
percentile of all genes. (d) GSEA results for the ER alpha target gene sets defined by peak-based method (the green lines in (a)). Note that it
cannot detect the activity difference of ER alpha between ER+ and ER- samples.
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makes the tissue more susceptible to tumor development
[59,60]. Stat1 may function as a tumor suppressor via in-
teraction with P53 or BRAC1 [61,62], or by up-regulating
P27Kip1 expression [63]. In addition, Stat1-deficient mice
can spontaneously develop estrogen receptor α-positive
luminal mammary carcinomas [59]. At the mRNA level,
we found that expression of Stat1 was significantly re-
duced in tumor cells compared to normal breast tissues
(P=2e-8, t-test). Together with the observed activity en-
hancement of Stat1, we posit that Stat1 might act mainly
as a repressor in gene transcriptional regulation.
Next, we compared tumor stroma samples (ISS and
INVS) with normal stroma samples (NS). At the signifi-
cance level FDR<0.05, we identified Baf155, Ini1, Gr,
Znf274 and Fosl1. We also compared tumor epithelium
samples (ISE and INVE) with normal epithelium sam-
ples (NE) using REACTIN. Compared to stroma results,
more TFs were identified for epithelium comparison
(Table 2). Our results indicate Stat1 and Stat2 show dif-
ferential activities between tumor and normal breast epi-
thelium samples. E2F1 and E2F4 are also identified as
TFs with higher activities in tumor epithelium samples,
suggesting higher proliferative rate of malignant epi-
thelium breast cells. E2F1 and E2F4 play the important
regulatory role in cell cycle and many studies have dem-
onstrated their importance during tumorigenesis [64,65].
In addition, ER alpha shows higher activity in malignant
epithelium cells than in normal epithelium cells. How-
ever, no ER alpha activity difference is observed between
malignant and normal stroma cells, suggesting that the
roles played by ER alpha during breast cancer carcino-
genesis is cell type specific.
Finally, we inferred the regulatory activity difference of
TFs by comparing ISE with NE, INVE with NE, ISS with
NS, and INVS with NS. This analysis gives rise to the
regulatory programs underlying each of the breast can-
cer subtypes (Additional file 3: Table S3).
Our analysis also suggests that the REACTIN algorithm
is more sensitive in detecting the differential activity of
TFs when applied to more specified cancer subtypes. For
example, when the pooled tumor samples were compared
against pooled normal samples, only two TFs (Stat1 and
Stat2) were identified. However, when INVE samples were
compared with NE samples, 192 TF binding profiles
showed significant differential activity at the FDR<0.05
significance level (Additional file 3: Table S3). This is due
to the heterogeneous nature of tumor samples. Each
tumor sample may have its own specific regulatory pro-
gram, and therefore pooling different tumor samples
would reduce the ability of REACTIN to detect the differ-
ential regulatory programs (presumably because no single
program is shared amongst all these samples). In contrast,
tumor samples of the same subtype are more likely to
share common regulatory programs and thus be more
amenable to detection by the REACTIN algorithm.
Identification of transcription factors associated with
survival of patient with breast cancer
We then adapted the REACTIN algorithm to identify
TFs associated with survival of patients with breast
cancer. To achieve this, we modified the REACTIN
algorithm to calculate a regulatory score of a TF for each
Table 2 TF binding profiles with significantly different
activities between breast tumor and normal breast
tissues
Tumor (38) versus normal (28): FDR <0.05
TF Cell line Condition Lab RAS Location P-value
Stat1 K562 Ifnah6h Sydh 6.252 0.164 0
Stat2 K562 Ifnah6h Sydh 6.274 0.164 0
Stat1 K562 Ifnah30 Sydh 5.674 0.159 0
Stat2 K562 Ifnah30 Sydh 5.287 0.157 0
Tumor stoma (20) versus normal stroma (14): FDR<0.05
TF Cell line Condition Lab RAS Location P-value
Baf155 Helas3 Sydh 5.095 0.260 0
Gr A549 Dexc Haib 5.119 0.225 0.004
Ini1 Helas3 Sydh 4.973 0.252 0.003
Gr A549 Dexc Haib 5.125 0.249 0.003
Znf274 Helas3 Sydh 5.207 0.326 0.01
Fosl1 K562 Haib 4.888 0.298 0.003
Pu1 K562 Haib 5.221 0.298 0
Tumor epithelium (18) versus normal epithelium (14) top 20
TF Cell line Condition Lab RAS Location P-value
E2f4 Helas3 Sydh 6.151 0.178 0
Stat1 K562 Ifna30 Sydh 5.726 0.235 0
E2f4 K562b Sydh 5.158 0.165 0
Stat2 K562 Ifna30 Sydh 5.788 0.239 0
Stat1 K562 Ifna6h Sydh 5.857 0.239 0
Stat2 K562 Ifna6h Sydh 5.469 0.238 0
E2f1 Helas3 Sydh 5.290 0.167 0
Eralphaa T47d Dmso2 Haib 5.042 0.236 0
Irf3 Helas3 Sydh 4.947 0.235 0
E2f1 Mcf7 Sydh 4.962 0.166 0
Stat1 Helas3 Ifng30 Sydh 4.831 0.205 0
Eralphaa T47d Gen1h Haib 4.726 0.167 0.002
Stat1 K562 Ifng6h Sydh 4.781 0.236 0.002
Nyfb K562 Sydh 4.751 0.116 0
Baf170 Helas3 Sydh 4.688 0.195 0.004
Eralphaa T47d Estradia1h Haib 4.726 0.167 0.002
Nyfa K562 Sydh 4.627 0.214 0.
Sta1 K562 Ifng30 Sydh 4.635 0.236 0.001
Sp1 K562 Haib 4.547 0.214 0.001
Zhu et al. BMC Genomics 2013, 14:504 Page 7 of 16
http://www.biomedcentral.com/1471-2164/14/504
samples in a microarray dataset (see “Methods” for de-
tails), resulting in an activity profile for each TF binding
profile in our ChIP-seq data collection. We calculated
the activity scores of all TFs in all samples in the Vijv
dataset [46].
First, we examined whether the inferred activity score
of ER alpha reflected its actual activity in a sample. We
compared activity scores of ER alpha in ER+ versus ER-
breast cancer samples. As shown in Figure 4, the activity
scores of ER alpha are significantly higher in ER+ than
in ER- samples with the exception of Ecc1_ERapha_
Dmso2. This suggests that the inferred activity score of
ER alpha can correctly reflect the ER status of a breast
cancer sample. We compared the activity scores of all
TF binding profiles in ER+ versus ER- samples using
Wilcox rank sum test (Additional file 4: Table S4). We
find that out of the 424 TF binding profiles we collected,
29 have significantly higher activity scores in ER+ samples
and 135 have significantly higher activity scores in ER-
samples. Consistent with the results of the REACTIN
algorithm, the top three most significant TFs with higher
activity scores in ER+ than in ER- are ER alpha, FOXA1
and GATA3.
We then fitted a cox proportional hazard model for
each activity profile to identify TFs that were correlated
with patient survival time. We identified a total of 35 TF
binding profiles that were significantly associated with
breast cancer patient survival. Most of them were still
significant even after considering the ER status and node
status using the multiple variable model (Table 3). Here
we use the Sydh_Helas3_E2f4 binding profile as the ex-
ample to show the relationship between patient survival
and E2F4 activity. As shown in Table 3, E2F4 is sig-
nificantly associated with patient survival with a hazard
ratio of 1.291 (95% CI is [1.137, 1.467]) without consid-
ering ER status. After considering the ER status and
node status, it is still significant with a hazard ratio of
1.237 and a 95% CI of [1.094, 1.4]. In contrast, the ex-
pression levels of E2F4 cannot predict patient survival
time (P>0.1 for both single and multiple variable Cox re-
gression models).
Out of the 260 breast cancer samples of the Vijv
dataset, 151 have a positive E2F4 activity score and 101
have a negative E2F4 activity score. Figure 5a shows
two samples with an E2F4 regulatory score of −41.5 and
5.95, respectively. As shown, in the sample with a nega-
tive score genes with higher probability of being E2F4
regulated are more likely to have lower expression levels
(i.e. biased to the right side), whereas in the sample with
















































































Figure 4 The activity scores of six TF binding profiles for ER alpha in ER+ and ER-. The P-values in the top-right corner are calculated
based on Wilcox rank sum test. The six TF binding profiles are from two cell lines (T47d and Ecc1) and under three different conditions (treated
with steroid hormone Gen/Estradia for 1h, or with Dmso2 as control).
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E2F4 activity scores in the 260 samples is shown in
Figure 5b. Patients with positive E2F4 activity scores
(E2F4>0) demonstrate significantly shorter survival
time than patients with negative E2F4 activity scores
(E2F4<0) with a P-value of 4e-7 (Figure 5c). We note
that the ER+ patients show significant longer survival
time than ER- patients with P-value of 4e-6. In another
words, the inferred activity score of E2F4 achieves better
accuracy than ER status when predicting survival time of
patients. Combining E2F4 activity score with ER status,













Sydh_helas3_E2f6 5.96E-06 0.0017 1.073 (1.041, 1.106) 8.44E-05 0.0163 1.064 (1.032, 1.097)
Sydh_K562_Cfos 1.03E-05 0.0017 1.114 (1.062, 1.168) 0.0001 0.0163 1.099 (1.047, 1153)
Sydh_K562_Stat1_Ifng30 1.17E-05 0.0017 1.264 (1.138, 1.403) 0.0002 0.0163 1.221 (1.099, 1.358)
Sydh_K562_Brf2 2046E-05 0.0019 1.172 (1.089, 1.262) 0.0003 0.0163 1.147 (1.065, 1.235)
Sydh_K562_Brf1 2.52E-05 0.0019 1.228 (1.116, 1.350) 0.0003 0.0163 1.192 (1.084, 1.311)
Sydh_K562_Cmyc_Ifng6h 2.62E-05 0.0019 1.322 (1.163, 1.513) 0.0005 0.0168 1.271 (1.111, 1.453)
Sydh_Helas3_Ini1 3.67E-05 0.0020 1.292 (1.144, 1.460) 0.0004 0.0168 1.240 (1.100, 1.396)
Sydh_K562_Tf3c110 3.85E-05 0.0020 1.221 (1.110, 1.343) 0.0003 0.0163 1.193 (1.085, 1.312)
Sydh_K562b_Znf274 4.74E-05 0.0022 1.236 (1.116, 1.369) 0.0006 0.0168 1.198 (1.081, 1.328)
Sydh_K562_Cmyc 5.50E-05 0.0023 1.290 (1.140, 1.461) 0.0006 0.0168 1.242 (1.098, 1.405)
Haib_Gm12878_Atf3 5.84E-05 0.0023 1.230 (1.112, 1.361) 0.0003 0.0163 1.201 (1.088, 1.327)
Sydh_Hepg2_Srebp1 7.36E-05 0.0024 1.211 (1.102, 1.332) 0.0005 0.0168 1.191 (1.080, 1.313)
Sydh_Helas3_E2f4 8.36E-05 0.0024 1.291 (1.137, 1.467) 0.0007 0.0182 1.237 (1.094, 1.400)
Sydh_K562_Cmyc_Ifng30 9.17E-05 0.0024 1.254 (1.120, 1.405) 0.0006 0.0172 1.225 (1.090, 1.376)
Sydh_K562_Cjun_Ifng6h 0.0001 0.0027 1.291 (1.134, 1.469) 0.0014 0.0220 1.233 (1.084, 1.402)
Sydh_K562_Ccnt 0.0001 0.0028 1.345 (1.156, 1.564) 0.0012 0.0220 1.303 (1.110, 1.530)
Sydh_K562b_Gata2 0.0001 0.0028 1.128 (1.061, 1.200) 0.0017 0.0227 1.106 (1.039, 1.178)
Sydh_K562_Irf1_Ifng6h 0.0001 0.0030 1.185 (1.086, 1.293) 0.0009 0.0215 1.159 (1.062, 1.624)
Sydh_K562_Bdp1 0.0002 0.0033 1.233 (1.106, 1.375) 0.0020 0.0246 1.190 (1.066, 1.330)
Sydh_K562_Rpc155 0.0002 0.0035 1.410 (1.177, 1.689) 0.0012 0.0220 1.353 (1.127, 1.624)
Haib_Hepg2_Rxra 0.0002 0.0035 1.210 (1.095, 1.338) 0.0013 0.0220 1.179 (1.067, 1.303)
Sydh_K562_Hmgn3 0.0002 0.0035 1.180 (1.082, 1.288) 0.0156 0.0620 1.122 (1.022, 1.233)
Uw_K562_Ctcf 0.0002 0.0035 1.298 (1.131, 1.490) 0.0013 0.0220 1.268 (1.097, 1.465)
Haib_Hepg2_Fosl2 0.0002 0.0039 1.419 (1.177, 1.711) 0.0015 0.0220 1.360 (1.125, 10645)
Haib_Hepg2_Hdac2 0.0003 0.0040 1.178 (1.079, 1.286) 0.0019 0.0241 1.150 (1.053, 1.255)
Sydh_K562_Brg1 0.0003 0.0040 1.106 (1.048, 1.168) 0.0038 0.0317 1.085 (1.027, 1.358)
Haib_Hepg2_Gabp 0.0003 0.0043 1.238 (1.103, 1.390) 0.0017 0.0227 1.207 (1.074, 1.358)
Sydh_Gm12878_Ctcf 0.0003 0.0045 1.333 (1.140, 1.558) 0.0012 0.0220 1.290 (1.106, 1.504)
Haib_Hepg2_Sp1 0.0003 0.0045 1.153 (1.067, 1.247) 0.0014 0.0220 1.135 (1.050, 1.226)
Haib_Gm12878_Bcl11a 0.0003 0.0045 1.220 (1.094, 1.361) 0.0012 0.0220 1.194 (1.072, 1.329)
Sydh_Mcf7_Hae2f1 0.0004 0.0045 1.224 (1.095, 1.367) 0.0004 0.0168 1.228 (1.096, 1.376)
Sydh_Helas3_Cjun 0.0004 0.0045 1.075 (1.033, 1.118) 0.0028 0.0293 1.063 (1.021, 1.106)
Haib_Hepg2_Sin3ak20 0.0004 0.0045 1.368 (1.151, 1.626) 0.0014 0.0220 1.323 (1.114, 1.571)
Sydh_K562_Stat1_Infa6h 0.0004 0.0045 1.273 (1.114, 1.455) 0.0032 0.0295 1.222 (1.069, 1.397)
Sydh_Ntd1_Znf274 0.0004 0.0049 1.204 (1.086, 1.336) 0.0026 0.0286 1.174 (1.058, 1.303)
The hazard ratio and 95% confidence interval (CI) are calculated using cox proportional hazards model with single variable or multiple variables. In the multiple
cox regression model, ESR (Estrogen receptor status) and Posnodes (lymph node status) are included as variables together with the inferred TF activity scores.
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we divided samples into four categories as shown in
Figure 5d. In ER+ samples, patients with positive E2F4 ac-
tivity still have significantly shorter survival time than
those with negative E2F4 activity (P=1e-5). In ER- sam-
ples, the same trend can also be observed, although the
difference is not significant due to small sample size.
Comparison with other methods
The REACTIN algorithm extends GSEA analysis by
adopting a probabilistic representation of gene sets.
Namely, instead of using a defined gene set, it regards all
genes as members of a gene set with different proba-
bilities. This extension is very suitable for the TF-gene
regulatory relationships defined by ChIP-seq or ChIP-
chip experiments. In fact, there exist both strong and
weak binding of TFs with their targets. As such TF-gene
interactions should be represented in a quantitative ra-
ther than in a binary manner. Despite of this, we defined
a target gene set for all TF binding profiles in our ChIP-
seq collection for comparison purpose. For a TF, target
genes are defined as those with at least one binding peak
of the TF in its promoter regions (from 1000 bp up-
stream to 500 bp downstream of their TSS). We then
applied GSEA analysis to identify TFs with target gene
sets enriched in differential expression profiles between
ER+ and ER- breast cancers. It is observed that GSEA is
less sensitive: it identified ER alpha as the significant TFs
in only 7 of the 10 datasets. It failed to identify ER alpha
in the Desm, Hess and Ivsh datasets (Additional file 5:
Table S5). It also failed to identify FOXA1 and GATA3
in all of the 10 datasets.
We also performed GSEA analysis using TF target gene
sets defined by TIP method, which failed to identify ER
alpha in 5 of the 10 datasets (Additional file 6: Table S6).
In addition, we examined the TF target gene sets defined
by the ChEA database. GSEA analysis using these gene
sets identified ER alpha in only one dataset (Additional
file 7: Table S7). Thus, we conclude that the REACTIN
algorithm outperforms GSEA analysis in identifying re-
gulatory programs underlying cancer.
Discussion
In this article, we have introduced a new algorithm
named REACTIN that integrated gene expression data
with TF binding data to identify TFs with significantly dif-
ferential activity between two sample groups. REACTIN
operates under a similar framework to that of GSEA,
which has been widely used to identify gene sets associ-
ated with an interested phenotype. Theoretically, we can
utilize GSEA analysis to identify disease associated TFs, if
we define a gene set for each TF. However, we instead
adopt a quantitative method to measure TF-gene regula-
tory relationships in REACTIN for two reasons. First, as
with many biological processes, TF-gene binding events
should be regarded as a quantitative and continuous vari-
able rather than a simple on/off switch model. For any
given TF, there exists strong and weak binding sites in the
genome, both contributing to transcriptional regulation of
genes. Thus, we believe a continuous representation of
TF-gene binding can be more accurately reflect the overall
nature of TF-gene regulatory relationships. Second, it is
often technically difficult to set up a cut-off for defining
Figure 5 The relationship between survival time of patients with breast cancer and inferred E2F4 activity score. The Vijv dataset is used
in the calculation. (a) Two breast cancer samples with an E2F4 regulatory score of −41.5 and 5.95, respectively. (b) Distribution of E2F4 activity
scores in the 260 samples. (c) The survival curves of patients with breast cancer. “E2F4>0” shows patients with positive E2F4 activity scores;
“E2F4<0” shows patients with negative E2F4 activity scores. (d) The survival curves of four categories patients: ER+ & E2F4>0, ER+ & E2F4<0, ER- &
E2F4>0 and ER- & E2F4<0. E2F4 activity score is inferred based on the Sydh_Helas3_E2F4 binding profile.
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target genes of a TF based on its ChIP-seq data. For ex-
ample, given the ChIP-seq data of a TF, we usually define
target genes as those with one or more binding peaks in
their promoter regions. The definition of promoter region
is often arbitrary, e.g. 1 kb or 5 kb around the TSS have
been used in previous publications. For these two reasons,
the gene set based method cannot fully utilize the TF
binding information derived from ChIP-seq data and is
ultimately less robust than REACTIN, as has been shown
by our results (Additional file 5: Table S5 and Additional
file 7: Table S7).
The REACTIN algorithm calculates a regulatory score
and assesses its significance for each TF by comparing
and permuting the case and control samples. In this arti-
cle, we also showed a modified version of this algorithm.
In the modified version, we calculated a regulatory score
of a TF for each individual sample, yielding an activity pro-
file of the TF. Given the profile, we can compare its in-
ferred activities in case and control samples (e.g. using
Wilcox rank sum test) to examine the activity difference
of a TF (Additional file 4: Table S4). Then, what is the re-
lationship of the two methods for identifying TFs with sig-
nificant differential activities between case and control?
This is analogous to the problem of identifying differen-
tially expressed genes from case–control microarray data.
In general, two categories of methods have been widely
used. One is to directly compare expression levels of genes
between case and control using t-test or Wilcox rank sum
test. The other category, typified by SAM (Statistical Ana-
lysis of Microarrays) [66], adopts a permutation-based
strategy to take into account correlation structure and
correct for multiple testing. The REACTIN algorithm
applies a similar strategy as SAM, while the modified
method is similar to the test based method for identi-
fying differential expressed genes. Practically, the re-
sults REACTIN is much more conservative than the
modified method, resulting in only the most confident
TFs. The modified version identifies more TFs that
show differential activities between case and control
(Additional file 3: Table S3). In addition, it is more
flexible by providing TF activity information in each
individual sample. For example, as we have shown, it
can be used to identify TFs associated with patient sur-
vival (Additional file 8: Table S8).
In Figure 2, we show that the cell line and the condi-
tions governing ChIP-seq experiments would result in
different TF binding profiles and impact the REACTIN
results. In fact, bindings of many TFs are tissue specific
and condition dependent. For example, a TF may have
different targets genes in tumor and normal tissues.
Ideally, we should use ChIP-seq data from tissue and
conditions that match with the gene expression data.
For example, as shown ChIP-seq in T47d (steroid hor-
mone treated) can more accurately capture TF-gene
binding relations in breast cancer than ChIP-seq in
Ecc1 cell lines.
Conclusion
In this study, we proposed a method called REACTIN to
identify TFs that exhibit significantly differential activity
between the disease samples versus the normal controls.
The method integrates the case-control gene expression
data with the TF binding data from ChIP-seq experi-
ments. We applied REACTIN to compare ER+ with ER-
samples in ten breast cancer datasets and successful
detected the activity difference of ER alpha, FOXA1 and
GATA3 between ER+ and ER- breast cancer subtypes.
We also demonstrated the effectiveness of applying
REACTIN to identify TFs that were predictive to sur-
vival times of patients with breast cancer. REACTIN
provides a useful tool to investigate regulatory programs
underlying a disease, and more generally underlying any
biological processes, providing the related case and con-
trol gene expression data. As the available pool of ChIP-
seq data increases, we expect a wide application of the
REACTIN algorithm to the study of regulatory mecha-
nisms governing different human diseases.
Methods
Microarray gene expression datasets
All the microarray data used in this study were down-
loaded from the public Gene Expression Omnibus (GEO)
databases or from the websites provided by the original
publications (Additional file 1: Table S1). In most of the
datasets gene expression was measured as absolute values
by one-channel arrays, while in the others relative expres-
sion levels were provided from two-channel cDNA arrays.
The two types of datasets were processed in different
ways. In microarray data, some genes are represented
by multiple probesets. When multiple probe sets were
mapped to the same gene, their values were averaged
to represent the expression level of the gene for datasets
from two-channel arrays, whereas the probe set with the
maximum average value was used for datasets from one-
channel arrays.
Calculation of binding affinity of transcription factors
with genes
ChIP-seq data provide binding information of a TF at
each nucleotide in a genome (i.e. the number of reads
covering the nucleotide). Based on ChIP-seq data, we
calculated the binding affinity of a TF with all human
Refseq genes using a probabilistic model called TIP (Tar-
get Identification from Profile) [31]. For a TF, TIP builds
a characteristic, averaged profile of binding around the
TSS of all genes and then uses this profile to weight the
sites associated with a given gene, providing a continuous-
valued score of this TF for each gene. The score provides
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a metric that quantifies the binding affinity of a TF with a
gene. We downloaded a total of 424 ChIP-seq track files
from the ENCODE project [39,67], representing binding
profiles of >120 human TFs in different cell lines or condi-
tions. For each track file, we applied TIP [31] to calculate
the binding affinities of the TF with all human Refseq
genes, resulting in a total of 424 TF binding affinity pro-
files. We note that the binding profile of a TF can also be
calculated based on the ChIP-chip data of the TF in the
same way.
Transformation of binding affinity to binding score
We represented the above calculated binding affinity
profiles as a matrix |A|, where ai,j was the binding affin-
ity of TF j with gene i. Then we calculated the probabil-
ity of a gene being regulated by a TF. Given the binding
affinity profile of the jth TF, a•,j, we calculated the z-score
for gene i as zi,j = (ai,j-mean(a•,j))/sd(a•,j), where mean(a•,j)
and sd(a•,j) are respectively mean and standard deviation;
and then estimated the corresponding p-value by referring
to a standard normal distribution.
This resulted in a p-value matrix |P| containing the p-
values for all genes in all ChIP-seq tracks. The elements
in |P| was subsequently transformed into non-negative
values by taking –log10 (Pi,j) and truncated at 10
(namely, set the value to 10 if –log10(Pi,j)>10) to obtain
the matrix |S′|. The goal of truncation at 10 is to avoid
the influence of extreme values in subsequent analysis.
After this transformation, -log10 (P) follows an exponen-
tial distribution.
Finally, we normalized |S′| into a matrix |S| by the fol-
lowing si,j = (s'i,j-min(S'))/(max(S')-min(S')), where min
(S') and max(S') are minimum and maximum values of
|S'|, respectively. After this transformation, all elements
in |S| take a value raging from 0 to 1, with a higher
value of si,j indicating a higher probability of gene i being
regulated by the corresponding TF in ChIP-seq track j.
Regulatory activity inference (REACTIN) for transcription
factors
Many gene expression experiments follow a case–con-
trol design to investigate the mechanism of a disease,
where expressions of genes are compared between a case
group (e.g. tumor samples from breast cancer patients)
and a control group (e.g. samples from normal breast
tissues). With this type of data, we propose a method
called REACTIN (REgulatory ACTivity INference) to
identify transcription factors (TFs) that show significantly
differential activities between the case and the control
groups. REACTIN calculates a RAS for a TF using a pro-
cedure similar to the gene set enrichment analysis (GSEA)
[38]. In contrast to the GSEA method, REACTIN does
not take a gene set (e.g. the target gene list of a TF) as the
input, instead, it utilizes the regulatory potential of a TF to
all genes calculated from ChIP-seq data. In practice, the
|S| matrix described in the preceding section is used.
Given a gene expression data (a case–control data with
n1 case and n2 control samples) and the regulatory po-
tential profile of a TF (a column from matrix |S|, de-
noted as s=(s1, s2, …, sg), where g is the total number of
genes), we calculate the RAS for this TF using the fol-
lowing procedure.
1) We calculated the t-score for each gene by
comparing its expression levels in the two sample
groups, t ¼ μ1−μ2ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
δ21=n1þδ22=n2
p , where μ1, μ2 are means
and δ1, δ2 are standard deviations of expression
levels of the gene in case and control samples.
Subsequently, all genes are sorted in the decreasing
order of their t-scores to obtain a ranked t-score
vector t'=(t(1), t(2), …., t(g)), and accordingly, the
vector s is reordered to s'=(s'1, s'2, …, s'g). In some
case control data, gene expression is measured in
paired samples (e.g. tumor versus adjacent normal
tissue). In these cases, we used paired t-test to
calculate the t-scores of genes to increase the
statistical power: t ¼ μdδd , where di is the expression
difference of a gene between the matched case and
control of sample i.
2) We defined two non-decreasing functions, a
foreground function f(i) and a background function
b(i), based on the two vectors t' and s' as follows:
3)
f ið Þ ¼ ∑
i
k¼1 t kð Þ
2s0k
 
∑gk¼1 t kð Þ
2s0k
  ; 1≤i≤g;
4)
b ið Þ ¼ ∑
i





∑gk¼1 t kð Þ
2 1−s0 kð Þ
  ; 1≤i≤g:
5) We compared the difference between the
foreground function and the background function
at each position i to obtain the maximum value
(ps+) and the minimum value (ps-) of f(i)-b(i).
6) ps+ =max(f(imax) − b(imax), 0), where imax ¼ arg
max
i¼1;2;…;g
f ið Þ−b ið Þf g.
7) ps+ =max(f(imax) − b(imax), 0) where imin ¼ arg
min
i¼1;2;…;g
f ið Þ−b ið Þf g.
8) A pre-score is then defined as ps=ps+, if ps+>|ps-|;
and otherwise ps=ps-.
9) Normalization of pre-score into a normalized
score, which we denoted as regulatory activity
score (RAS). To achieve this, we shuffled the
sample tags of the two groups, re-calculated the
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t-scores for all genes and repeated step 1–3 to
obtain a permuted ps+ and a permuted ps-.
Specifically, we used a balanced permutation
strategy by randomly selecting n1/2 samples from
case group and n2/2 samples from the control
groups to form the shuffled case group and using
the remaining samples as the shuffled control
group. We performed a total of m times of
permutations (e.g. m=1000), resulting in a vector
psperm+ and a vector psperm-. The RAS was
calculated by normalizing against the permuted
ps-scores:
10) RAS = ps/mean(psperm +), if ps≥0; and otherwise,
RAS = ps/|mean(psperm −)|.
11) Calculation of p-value for RAS. The significance of
a RAS can be calculated based on the m times of
permutations. If ps≥0, then p-value is calculated as
the fraction of elements in psperm+ that are equal to
or greater than ps; otherwise, p-value is calculated
as the fraction of elements in psperm- that are equal
to or less than ps.
12) Calculation of false discovery rate (FDR). Typically,
we would calculate the RAS for a large number of
TFs (e.g. in matrix |S|, we have 424 TF binding
profiles generated by the ENCODE project). To
correct for multiple testing, we calculated the FDR
of each TF, also based on permutations. The RAS
for a TF is a normalized score and is directly
comparable between different TFs. Thus, we
normalized the permutated pre-scores in psperm+
and psperm- for all TFs and used them to calculate
the FDR of each TF. For a TF with regulatory
activity score of RAS*≥0, its FDR was calculated as
the ratio of the percentage of all normalized
psperm+ scores with a value ≥RAS*, divided by the
percentage of observed RASs with a value ≥RAS*;
and similarly for a TF with RAS*<0.
Calculation of individual regulatory activity score of
transcription factors in each sample
In some cases, we need to calculate the regulatory ac-
tivity scores of a TF in each of the samples. For example,
in order to identify TFs associated with patient survival,
we may calculate the individual RASs (we called them
iRASs to discriminate them from the iRASs calculated
by case versus control comparison) of TFs in all samples
and then correlate them with patient survival times. To
achieve this purpose, we modified the above-described
procedure to calculate sample-wise iRASs for TFs.
For microarray data that measures the relative expres-
sion levels of genes (e.g. data from experiments using
two channel cDNA arrays), we just replaced the t-score
profile with each individual relative expression profile in
step 1 to calculate the pre-scores of TFs in that sample
(step 2–3). To normalize the pre-score, we permuted
genes to obtain shuffled gene expression profiles, calcu-
lated the permuted pre-scores and normalized the ob-
served scores based on them using a similar method as
described in step 4.
If the microarray data provide the absolute values
of gene expression levels (e.g. data from one-channel
Affymetrix arrays), we performed an additional norma-
lization step to transform absolute expression into relative
expression levels. Specifically, we first performed quantile
normalization [68] for all expression profiles, so that each
sample in the dataset achieved exactly the same distri-
bution. Then for each gene, we divided its values by the
median expression levels in all samples and took log10
transformation to obtain the relative expression levels.
Subsequently, the iRASs of TFs in all samples can be
calculated using the method described in the previous
paragraph.
Identification of transcription factors associated with
patient survival
Given the calculated iRAS profiles of TFs in all samples,
we used the Cox proportional hazards model to identify
TFs that were predictive to survival time of patient with
breast cancer. The model was designed in the following
form: logh tð Þ ¼ logh0 tð Þ þ β0x0 þ ∑
p
i¼1
βixi , where x' is the
RAS profile for a TF, x=(x1, x2, …, xp) are p confounding
factors (e.g. tumor size, estrogen receptor status, etc.), h0
(t) represents basic function of risk, and h(t) represents
hazard rate at time t. We examined the iRAS profiles of
all TFs one by one, each time including a single TF and
a selected list of confounding factors as the predictive
variables. The TFs with significant coefficient (P<0.001)
were identified as those associated with patient survival.
These TFs provide additional predictive power than the
confounding factors. In practice, we only selected the
significant clinical features as the confounding factors in
our model. The significant clinical features are those
with P<0.01 in a full model that includes all the
confounding features. In the Vijv dataset, ER status and
positive node status are the two clinical features that are
significant and included as the confounding factors. The
R package “survival” was used to implement the Cox re-
gression model.




Additional file 1: Table S1. Breast cancer datasets used in this study.
Additional file 2: Table S2. Activity differences of TF profiles between
ER+ and ER- breast cancer samples in 10 datasets. In each dataset, the
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top 10 TF profiles are shown. Significant profiles (FDR<0.25) are
highlighted in blue color.
Additional file 3: Table S3. Activity differences of TF profiles between
different breast cancer subtypes and normal breast tissue in Ma dataset.
The data contains 6 pairs of comparison: ISE vs. NE, INVE vs. NE, ISE+INVE
vs. NE, ISS vs. NS, INVS vs. NSS, and ISS+INVS vs. NS. NE: normal
epithelium; NS: normal stroma; ISE: in situ epithelium; INVE: invasive
epithelium; ISE: in situ stroma; INVS: invasive stroma.
Additional file 4: Table S4. Difference of activity scores of TF binding
profiles between ER+ and ER- samples in Vijv dataset. Given a TF binding
profile, a regulatory score is calculated for each sample and then the
scores are compared between ER+ and ER- samples using the one-sided
Wilcox rank sum test.
Additional file 5: Table S5. GSEA results using TF target gene sets
defined based on peak-based method. For each TF binding profile, target
genes are defined as those with at least one binding peaks in their
promoter regions (1kb upstream to 500bp downstream of TSS of genes).
Peakseq method is used to determine binding peaks. ES: enrichment
score; NES: normalized enrichment score.
Additional file 6: Table S6. GSEA results using TF target gene sets
identified by TIP algorithm.
Additional file 7: Table S7. GSEA results using TF target gene sets
provided from ChEA database.
Additional file 8: Table S8. Association of TF activity scores with
survival time of patient with breast cancer in Vijv dataset. Given a TF
binding profile, a regulatory score is calculated for each sample. The
association of a TF profile with patient survival is calculated using cox
proportional hazard regression model. In the simple cox regression
model, the TF activity score is used as the single variable. In the multiple
cox regression model, TF activity score, ER status (ER+ or ER-) and lymph
node status (+ or -) are used as variables. The hazard ratio and its 95%
confidence interval are provided. P-values are adjusted using Benjamini
Hochberg multiple testing correction.
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